Thoracic Surgery Access Lumeda’s DigiLum dosimetry enables intraoperative photodynamic therapy during NSCLC thoracic procedures, offering surgeons a tool to shorten treatment time and potentially improve local control. Target outreach to thoracic surgeons, surgical oncologists, and hospital procurement to pilot DigiLum in operating rooms.

Clinical Partnerships Past collaboration with Roswell Park and ongoing clinical study plans position Lumeda as a partner for cancer centers and academic hospitals seeking evidence-driven PDT solutions. Propose joint trials, data sharing, and adoption through hospital trial networks.

AI Dosimetry Advantage DigiLum’s AI-enabled dosimetry and data capture can be positioned as a data analytics platform for treatment planning and outcome tracking, creating opportunities with hospital informatics teams and PDT device integrators looking to enhance planning capabilities.

Growth and Funding The recent Series A financing and leadership evolution signal a scalable growth trajectory. Engage strategic investors and OEM distributors interested in expanding a photonics and thoracic care device portfolio through co-marketing and distribution partnerships.

Market Readiness The photodynamic therapy field for thoracic cancers is gaining momentum as an intraoperative adjuvant approach, creating a favorable market for a data-driven dosimetry solution. Target oncology centers seeking precision PDT and explore collaborations with larger medtech players for broader deployment.